SCHEMBL7095748

SCHEMBL7095748

COC(=O)Cn1ccccc1=O

nearest known ligand 0.56

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
TSHR P16473 1/20 0.50
PSMB5 P28074 2/20 0.49
PSMB1 P20618 2/20 0.49
GAA P10253 1/20 0.48
POLB P06746 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ALDH1A1 P00352 1/20 0.47
HSD17B10 Q99714 1/20 0.47
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2851306 0.83 ALDH1A1 (0.55) KDM4ETSHRPOLBL3MBTL1ALDH1A1
SCHEMBL19500099 0.81 PSMB5 (0.52) SMN1; SMN2TSHRPSMB5PSMB1POLB
SCHEMBL28254025 0.81 KDM4E (0.50) KDM4ESMN1; SMN2TSHRPSMB5PSMB1
SCHEMBL9523478 0.81 KDM4E (0.47) KDM4ESMN1; SMN2TSHRGAAPOLB
SCHEMBL11964126 0.79 TSHR (0.54) KDM4ESMN1; SMN2TSHRPSMB5PSMB1
SCHEMBL19509381 0.79 PSMB5 (0.50) SMN1; SMN2TSHRPSMB5PSMB1POLB
SCHEMBL9752669 0.79 TSHR (0.57) SMN1; SMN2TSHRPSMB5PSMB1POLB
SCHEMBL21190075 0.78 GAA (0.51) TSHRGAAPOLBL3MBTL1
SCHEMBL1280773 0.77 TSHR (0.56) KDM4ETSHRPSMB5PSMB1POLB
SCHEMBL21334490 0.77 LMNA (0.49) KDM4ESMN1; SMN2TSHRPSMB1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116082237-B Nitrogen-containing heterocyclic compound and preparation method thereof 安徽中医药大学 2025-04-22 CN claimed
US-20210177851-A1 NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2021-06-17 US disclosed
EP-2861577-B1 TERTIARY AMINES, MEDICAMENTS CONTAINING SAID AMINES, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF BOEHRINGER INGELHEIM INT (DE) 2017-01-04 EP disclosed
US-8921243-B2 Fabrics comprising a photocatalyst to produce singlet oxygen from ambient oxygen VENTANA RESEARCH CORPORATION 2014-12-30 US disclosed
US-8921243-B2 Fabrics comprising a photocatalyst to produce singlet oxygen from ambient oxygen VENTANA RESEARCH CORPORATION 2014-12-30 US disclosed
US-8481446-B2 Chemically-resistant coating composition VENTANA RESEARCH CORPORATION 2013-07-09 US disclosed
US-8481446-B2 Chemically-resistant coating composition VENTANA RESEARCH CORPORATION 2013-07-09 US disclosed
US-20120135651-A1 Fabrics Comprising a Photocatalyst to Produce Singlet Oxygen from Ambient Oxygen VENTANA RESEARCH CORPORATION 2012-05-31 US disclosed
US-20120135651-A1 Fabrics Comprising a Photocatalyst to Produce Singlet Oxygen from Ambient Oxygen VENTANA RESEARCH CORPORATION 2012-05-31 US disclosed
WO-2011142838-A2 CHEMICALLY-RESISTANT COATING COMPOSITION LOMBARID JOHN L (US) 2011-11-17 WO disclosed
US-20100279850-A1 CHEMICALLY-RESISTANT COATING COMPOSITION VENTANA RESEARCH CORPORATION 2010-11-04 US disclosed
US-20100279850-A1 CHEMICALLY-RESISTANT COATING COMPOSITION VENTANA RESEARCH CORPORATION 2010-11-04 US disclosed
WO-2010118180-A1 FABRICS COMPRISING A PHOTOCATALYST TO PRODUCE SINGLET OXYGEN FROM AMBIENT OXYGEN LOMBARDI JOHN L (US) 2010-10-14 WO disclosed
EP-0815084-B1 LACTAM-CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MATRIX METALLOPROTEASE PROCTER & GAMBLE (US) 2003-08-27 EP disclosed
EP-0489458-B1 Hydroxyquinolone derivatives MERCK SHARP & DOHME (GB) 1995-06-07 EP disclosed
US-5252584-A Antagonist for treating nervous system disorders MERCK SHARP & DOHME LIMITED (GB) 1993-10-12 US disclosed
EP-0489458-A1 Hydroxyquinolone derivatives MERCK SHARP & DOHME LTD. (GB) 1992-06-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100279850-A1 CHEMICALLY-RESISTANT COATING COMPOSITION DNMT1, VCL, DNMT3L KDM4E 173/4885SMN1; SMN2 992/4885TSHR 4873/4885
US-20210177851-A1 NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS SOS1, SOS2, SOST KDM4E 3689/4885SMN1; SMN2 1069/4885TSHR 2962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.